
Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant at-a-glance

- Clinical-stage biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA, Raleigh-Durham, NC, and Dallas, TX

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company's robust immuno-dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, plaque psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is developing its lead product candidate, tapinarof cream, 1%, (DMVT-505), as a novel small molecule aryl hydrocarbon receptor agonist topical cream for the treatment of plaque psoriasis in adults and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively.

Management team

Todd Zavodnick

Chief Executive Officer

Philip M. Brown, MD, JD

Chief Medical Officer

Chris Chapman

Chief Commercial Officer

David Rubenstein, MD, PhD

Chief Scientific Officer

Michael Swartzburg

Chief Financial Officer

Christopher Van Tuyl, JD

General Counsel

Dermavant has four product candidates in development:

Plaque Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne

PRODUCT CANDIDATE	INDICATION	STAGE OF DEVELOPMENT				
		Preclinical	Phase 1	Phase 2	Phase 3	FDA Review
Tapinarof (DMVT-505) A topical, therapeutic AhR modulating agent, inhibiting several proinflammatory factors	Plaque Psoriasis					
	Atopic Dermatitis					
Cerdulatinib (DMVT-502) A topical dual JAK/Syk inhibitor	Vitiligo					
	Atopic Dermatitis					
Oxybutynin/Pilocarpine (DMVT-504) An oral combination of an immediate-release muscarinic antagonist with a delayed-release muscarinic agonist	Primary Focal Hyperhidrosis					
DMVT-503 A novel mechanism of action for the topical treatment of acne vulgaris	Acne Vulgaris					



1-8-DERMAVANT (1-833-762-8268)

Company locations:

Long Beach, California Office

Dermavant Sciences, Inc.
 3780 Kilroy Airport Way, Suite 250
 Long Beach, CA 90806

Raleigh-Durham, North Carolina Office


Dermavant Sciences, Inc.
 3300 Paramount Parkway, Suite 150
 Morrisville, NC 27560

Dallas, TX

Dermavant Sciences, Inc.,
 2102 E. State Hwy. 114, Suite 217
 Southlake, Texas 76092

Basel, Switzerland Office

Dermavant Sciences GmbH
 Viaduktstrasse 8
 4051 Basel



© 2022 Dermavant Sciences, Inc.
 All rights reserved. All trademarks are the property of Dermavant Sciences, GmbH.